The Linus Group
Items Needing Client Action
Ad previews delivered May 6 via the review portal; sent to Linus team via email "For Review: Health 2035 Report LinkedIn Ads Previews." Approval unblocks the $500/mo retargeting campaign launch (targeted week of May 12).
Awaiting Approval
V5 redelivered May 7 with corrected HSBC link (now hsbcinnovationbanking.com/us/en) across all assets. Already approved May 5; this is the final link-confirm step before publication (scheduled May 12).
Awaiting Approval
Five-email nurture sequence built and internally tested in Act-On May 6. Test emails to Kristin/Hamid pending. Final activation targeted May 14, gated on this approval and Email #3 content publishing.
Awaiting Approval
TLG-19 AEP — Email #3 Content Publishing Status
Tatjana noted on May 6 that Email #3 needs its referenced content piece published before the link can be added and the program activated. Information needed on publishing date so the AEP can move to live.
Info Needed
Newfangled In Progress
TLG-22: Shape Setup, Zapier Integration, Tracking Setup, Add to Launch Sheet
TLG-22: Campaign Activation
TLG-22: QA Completed
TLG-15: Executive Brief Publication on site
TLG-19: AEP Final Activation (after Email #3 content lands)
TLG-25: June Newsletter — Initial Development
TLG-25: June Newsletter — Strategy & Copy Review
TLG-25: June Newsletter — Email Generation & Internal Test
Recently Completed
TLG-24: April/May Newsletter ("Hamid at MATTER") sent to ~3,114 contacts
TLG-24: Test emails sent to client (Kristin, Hamid)
TLG-24: [Client] Email Approved
TLG-21: State of Young Physicians LinkedIn campaign — ad approved & activated ($800/mo)
TLG-21: Tracking Setup, Zapier Integration, Shape Setup, Add to Launch Sheet
TLG-22: Ad Previews created, Final Review & Sent to Client
TLG-15: Health 2035 Exec Brief — [Client] Design Approved
TLG-19: Emails Built & Internal Tests Sent (5-email AEP sequence)
TLG-19: Check Content for Publication
New Leads
18
+3 vs 15 prior week
Conversions
9
+2 vs 7 prior week
MQLs
2
-1 vs 3 prior week
SQLs
0
vs 0 prior week
Scoring criteria:
Hot — VP+/CXO/Director-level marketing, commercial, or strategy roles at life sciences tools, diagnostics, medtech, pharma, or biotech companies, with a conversion on a high-intent form and a business email domain.
Warm — Manager-to-Director marketing/commercial roles in target verticals, OR senior leaders with limited engagement, OR senior sales-side roles at relevant companies.
Cold — Converted leads in non-target verticals, unclear roles with low engagement, or business emails with no role/persona match.
Spam / Job Seeker — Personal email domains (gmail/hotmail/yahoo) with no name or enrichment.
All New Leads
CEO
Direct1 page view1 conversion
Converted On
Article: Are Life Science Tools Suppliers Losing Commercial Influence to AI?
Assessment
- CEO of Specac — UK-based scientific instruments manufacturer (FTIR sampling accessories), squarely in life sciences tools.
- Top-tier authority: full budget and strategic decision ownership.
- Business email + converted on the AI Research article — the campaign's core lead-gen asset.
- One page view limits the engagement signal; a quick personal outreach from Hamid or Ashley could quickly establish whether persuasion-model framing resonates.
Head Of Customer Insights
LinkedIn1 page view1 conversion
Converted On
Article: Are Life Science Tools Suppliers Losing Commercial Influence to AI?
Assessment
- 10x Genomics is a Tier-1 life sciences tools target (single-cell genomics, $400M+ revenue) — exactly the audience LINUS owns.
- Head of Customer Insights maps cleanly to the Influencer Persona 1 (Insights/Market Research Manager who needs executive-ready intelligence).
- LinkedIn-attributed conversion on the AI Research article validates the paid campaign hitting the right audience.
- Single page view; ideal candidate for a custom briefing offer that translates the AI Research findings to 10x's commercial context.
Director Of Sales & Marketing
LinkedIn1 page view1 conversion
Converted On
Article: Are Life Science Tools Suppliers Losing Commercial Influence to AI?
Assessment
- Diagnostics company in the underserved-segments territory LINUS flagged in the September 2025 positioning research.
- Director of Sales & Marketing — owns the commercial function and is a buyer-persona match for the Total Commercial Review offer.
- Personal yahoo email lowers enrichment confidence; the title and company are confirmed though.
- LinkedIn-attributed AI Research conversion suggests the campaign's mid-funnel framing hit a real pain point.
Vice President Of Marketing
LinkedIn1 page view1 conversion
Converted On
Article: Are Life Science Tools Suppliers Losing Commercial Influence to AI?
Assessment
- VP of Marketing — exact title match for Decision-Maker Persona 1.
- Daily Thermetrics is industrial process instrumentation, adjacent to but not core life sciences tools — partial vertical fit. Marketing leadership matters more than the vertical edge here.
- Business email + LinkedIn-attributed conversion on the campaign's flagship asset.
- Worth a tailored outreach that frames LINUS's persuasion model in industrial-instrument context to test cross-vertical resonance.
VP Sales
Direct5 page views1 conversion
Converted On
Insiders Signup
Assessment
- VP Sales at a health tech company — adjacent to the healthcare expansion segment.
- Five-page-view direct visit signals real intent (not a random LinkedIn click-through).
- Insiders Signup is a high-commitment conversion — self-selecting into VIP-tier content and direct contact with Hamid.
- Personal gmail address weakens enrichment; treat company affiliation as confirmed and validate role at first contact.
Account Executive
Direct37 page views1 conversion
Converted On
Insiders Signup
Assessment
- Harvard Bioscience is a clean life sciences tools fit; AE is a non-decision-maker title but indicates a real account-team interest.
- 37 page views is the standout engagement signal in this week's set — by far the deepest exploration.
- Insiders signup suggests serious interest in ongoing thought leadership, not a one-off content download.
- Likely worth surfacing internally — could be researching LINUS for someone else on the Harvard Bioscience commercial team.
Director, Alternate Site Sales — Mid Atlantic
Act-On1 page view0 conversions
Assessment
- Cepheid is a Tier-1 diagnostics company (Danaher subsidiary, GeneXpert) — strong vertical fit.
- Director-level sales role; not a primary decision-maker for marketing partners but adjacent and potentially influential.
- Act-On platform attribution suggests they came in via an existing nurture email rather than the paid campaign.
- Single-page-view, no conversion — limited engagement so far.
Regional Sales Director
Act-On1 page view0 conversions
Assessment
- Second Cepheid contact this week — pattern worth noting in case multiple visitors signal an internal evaluation.
- Regional Sales Director — same caveats as the other Cepheid contact (sales side, not marketing decision-maker).
- Act-On attribution suggests a nurture send, not the paid campaign.
- Per the April 29 multi-visitor company analysis initiative, Cepheid may warrant a deliberate enrichment pass to identify the marketing/strategy stakeholder.
Principal
LinkedIn1 page view1 conversion
Converted On
Article: Are Life Science Tools Suppliers Losing Commercial Influence to AI?
Assessment
- Sellular Biology is a small biotech consultancy/operator — Principal is a high-authority title, but the company size is below the Series A+ minimum LINUS set in February.
- Could still be a valuable advocate if Corey works with target companies as a consultant.
- LinkedIn paid attribution; clean conversion on the campaign's lead asset.
(Title not enriched)
Direct9 page views1 conversion
Converted On
Article: Are Life Science Tools Suppliers Losing Commercial Influence to AI?
Assessment
- Diagnostic Biochips email domain — life sciences instruments / diagnostics company.
- Nine page views is a strong engagement signal even without enrichment.
- Direct traffic + AI Research conversion suggests purposeful exploration.
- Title gap is the main risk — manual enrichment would clarify whether to escalate.
Chief Operating Officer and Company Director
Act-On1 page view0 conversions
Assessment
- COO at an Irish medical supply company — adjacent to LINUS's medtech audience but more distribution-focused than product-launch oriented.
- C-suite authority earns warm rather than cold.
- Act-On attribution + single page view + no conversion suggests a passive nurture click.
(No title)
Act-On6 page views0 conversions
Assessment
- Media services company — outside LINUS's life sciences/healthcare territory.
- Six page views is decent engagement; could be a media/PR-side contact researching for a client.
- No title and no conversion limits prioritization further.
(No title)
Act-On1 page view0 conversions
Assessment
- AMETEK is a large industrial instruments conglomerate — partial vertical adjacency, but no role/title visibility.
- Single page view, no conversion — baseline activity.
Founder
Act-On1 page view0 conversions
Assessment
- Title "Founder" at Elsevier (a long-established publisher) reads like an enrichment data quirk worth flagging.
- Publishing isn't a target vertical, and the role/company combination is unusual.
- Act-On nurture click; no conversion — minimal engagement.
(No title)
Act-On1 page view0 conversions
Assessment
- Vector Laboratories is a life sciences reagents/tools company — clean vertical fit on the company side.
- No title or seniority signal, single page view, no conversion — not enough to justify outreach yet.
- Worth tracking if a second Vector contact appears in coming weeks.
(No title)
Act-On1 page view0 conversions
Assessment
- Personal gmail address with no enrichment data, no name, no role — typical low-signal junk.
(No title)
Act-On3 page views0 conversions
Assessment
- Personal hotmail address, no enrichment, no real name. Three page views is mild but still no conversion.
(No title)
Google4 page views1 conversion
Assessment
- Personal gmail address with no enrichment. The conversion + Google attribution + four page views is unusual — the conversion form (Insiders Signup or similar) may indicate a real but anonymous individual subscriber rather than spam.
- If MQL/SQL criteria require a business email or named lead, this won't qualify.
Conversions by Source
Paid Media — LinkedIn Ads
Spend
$325.32
-7.1% vs $350.00 prior week
Clicks
59
-15.7% vs 70 prior week
CTR
0.67%
+0.09pp vs 0.58% prior week
CPC
$5.51
+10.2% vs $5.00 prior week
Conversions
13
-51.9% vs 27 prior week
CPA
$25.02
+93% vs $12.96 prior week
Monthly Budget Pacing
Active campaigns now total $2,000/month in committed daily budget — AI Research lead gen at $40/day (~$1,200/mo) plus the State of Young Physicians awareness campaign launched May 7 at $800/mo. The Health 2035 Report retargeting campaign (TLG-22, $500/mo) is queued pending client ad approval; once live, total spend will rise to ~$2,500/mo. Weekly spend during the report period was $325 — pacing in line with the $1,200/mo AI Research allocation since that was the only fully active campaign.
| Campaign | Spend | Clicks | Conv | CPA | Daily Budget | Status |
|---|---|---|---|---|---|---|
| NF — Lead Gen — Are Life Science Tools Suppliers Losing Commercial Influence to AI? | $280.00 | 24 | 7 | $40.00 | $40 | Active |
| NF — Website Visits — The Four Types of Skepticism | $45.32 | 35 | 0 | — | — | Paused |
| NF — Conversion — Fixing the Messy Middle LP | $0.00 | 0 | 6 | — | — | Completed |
AI Research lead gen continues to do the work — 7 conversions at $40 CPA, on-target for an upper-funnel campaign feeding the Executive Briefing offer. Conversions dropped vs prior week (13 vs 27), but the prior week's number was lifted by 6 conversions still being attributed to the now-completed Messy Middle LP campaign with no new spend behind them. Four Types of Skepticism is paused per the April 30 strategic decision to reallocate budget toward Young Physicians at launch. State of Young Physicians ($800/mo) launched May 7 — too late to appear in this period's data.
Email
Sent
3,114
vs 352 prior week
Open Rate
29.8%
-7.1pp vs 36.9% prior week
Click Rate
1.3%
-3.0pp vs 4.3% prior week
Campaigns
1
this period
| Campaign | Sent On | Sent | Open Rate | Click Rate |
|---|---|---|---|---|
| Hamid at MATTER (May Newsletter) | Mon May 5 | 3,114 | 29.8% | 1.3% |
The May newsletter (renamed from April after the date slip) hit the master Life Sciences list — 3,114 recipients, 29.8% open rate sits inside the 25–35% benchmark from the December 2025 baseline. Click rate of 1.3% is below the 2–5% benchmark, likely because the dominant CTA was the MATTER Chicago event (a Boston event for an audience that's nationally distributed) rather than a click-through to gated content. Direct comparison to the prior week's "Not Buying It — Buy on Amazon" send (352 recipients, 4.3% CTR) is apples-to-oranges — different list, different audience size, different CTA. Heads up: the connector flagged 553 unsubscribes (~17.8%) on this send. That's well outside normal range (typical: 0.1–0.5%) and almost certainly a data-pull artifact rather than a real list-hygiene event — worth a quick verification in Act-On directly.
Campaign Calendar — May 2026 – Jul 2026
Externally-visible milestones, sends, campaign launches, and client action items across the current month and the next two. Future-month items reflect current planning and may shift.
Newsletter
Article / Asset
Paid Media
Email Nurture
Event
Client Actions
May 2026
S
M
T
W
T
F
S
26
27
28
29
30
1
2
3
4
5
Newsletter
6
Ads Sent
7
TLG-21 Live
Brief V5
8
Ad Appr
Email Appr
9
10
11
12
TLG-22 Live
Brief Pub
13
MATTER Evt
14
AEP Live
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
Test Send
30
31
1
2
3
4
5
6
Jun 2026
S
M
T
W
T
F
S
31
1
Email Appr
2
Newsletter
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
1
2
3
4
Jul 2026
S
M
T
W
T
F
S
28
29
30
1
Newsletter
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
May 5
Hamid at MATTER (May Newsletter) — Sent
TLG-24
May 6
TLG-22 Ad Previews — Sent to Client
TLG-22
May 7
State of Young Physicians LinkedIn Campaign — Activated
TLG-21
May 7
Health 2035 Executive Brief V5 — Sent to Client
TLG-15
May 8
Client: TLG-22 Ad Approval
TLG-22
Client
May 8
Client: TLG-19 AEP Email Approvals
TLG-19
Client
May 12
TLG-22 Health 2035 Report Campaign — Activate
TLG-22
May 12
Health 2035 Executive Brief — Publish
TLG-15
May 13
MATTER Chicago — Hamid Fireside Chat
Event
May 14
TLG-19 AEP for Pharma/Biotech — Activate
TLG-19
May 29
Client: June Newsletter Test Email
TLG-25
Client
Jun 1
Client: June Newsletter Final Approval
TLG-25
Client
Jun 2
June Newsletter — Send
TLG-25
Jul 1
July Newsletter — Send
TLG-25
Campaign Progress
Approximate completion based on subtask milestones. Detailed status lives in Asana.
TLG-21: State of Young Physicians LinkedIn Campaign18/19 · 95%
TLG-15: Health 2035 Executive Summary17/20 · 85%
TLG-19: AEP for Pharma/Biotech Audience12/15 · 80%
TLG-22: Health 2035 Report LinkedIn Campaign12/17 · 70%
TLG-25: June Newsletter1/12 · 8%